Aberrant cystatin‑C expression in blood from patients with breast cancer is a suitable marker for monitoring tumor burden

Kwon,Woo  Sun; Kim,Tae  Soo; Nahm,Chung  Hyun; Moon,Yeonsook; Kim,Jin  Ju

doi:10.3892/ol.2018.9380

Aberrant cystatin‑C expression in blood from patients with breast cancer is a suitable marker for monitoring tumor burden

Authors:
- Woo Sun Kwon
- Tae Soo Kim
- Chung Hyun Nahm
- Yeonsook Moon
- Jin Ju Kim
View Affiliations

Affiliations: Song‑Dang Institute for Cancer Research, Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea, Department of Laboratory Medicine, Inha University College of Medicine, Incheon 22332, Republic of Korea
Published online on: September 3, 2018 https://doi.org/10.3892/ol.2018.9380
Pages: 5583-5590
Copyright: © Kwon et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was performed to evaluate the efficacy of circulating cystatin‑C as a tumor monitoring biomarker at different clinical time points in patients with breast cancer over a long‑term follow‑up period. In addition, the secretory rate of circulating cystatin‑C from cancer tissue was investigated by comparing the blood and tissue expression levels of cystatin‑C. Blood samples from healthy volunteers (40 males and 40 females) were obtained at yearly health examinations if laboratory and imaging abnormalities were not detected. Blood samples from 34 patients with breast cancer were obtained at 205 different time points of clinical progression. Blood levels of cystatin‑C were measured using ELISA and the tissue levels were measured using immunohistochemistry. No age‑associated effect was observed in male and female blood cystatin‑C levels. The positivity rate was 46% in patients (38/83) and 40% in samples collected at different time points (82/205). Blood cystatin‑C levels were lowest following surgery compared with patients with systemic metastasis (P<0.001). The sensitivity, specificity and accuracy rates of ELISA were 53.6, 63.6 and 53.9%, respectively. The concordance rate between blood and tissue expression was 38%. The main reason for discordance between tissue and serum expression of cytostatin‑C came from low serum positivity in samples showing tissue cytostatin‑C (3/11, 27%). The specificity between cytostatin‑C and CA‑125 was highest in tumor absence state. In conclusion, elevated blood levels of cystatin‑C were observed in 40% of breast cancer cases and were tumor‑volume dependent. However, the concordance rate between tissue and blood was quite low, suggesting tumor heterogeneity of cystatin‑C expression or co‑acting pathway activation, such as cathepsin D. As one‑third of breast cancer tissues express cystatin‑C without cancer antigen 15‑3 elevation, cystatin‑C may represent a good tumor‑monitoring marker in breast cancer.

View Figures

View References

1	Lankisch P, Wessalowski R, Maisonneuve P, Haghgu M, Hermsen D and Kramm CM: Serum cystatic C is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age. Pediatr Blood Cancer. 46:767–772. 2006. View Article : Google Scholar : PubMed/NCBI
2	Chew-Harris JS, Florkowski CM, George PM and Endre ZH: Comparative performances of the new chronic kidney disease epidemiology equations incorporating cystatin-C for use in cancer patients. Asia Pac J Clin Oncol. 11:142–151. 2015. View Article : Google Scholar : PubMed/NCBI
3	Magnusson M, Hedblad B, Engström G, Persson M, Nilsson P and Melander O: High and Cancer Study. J Int Med. 274:192–199. 2013. View Article : Google Scholar
4	Sheahan K, Shuja S and Murnane MJ: Cysteine protease activities and tumor development in human colorectal carcinoma. Cancer Res. 49:3809–3814. 1989.PubMed/NCBI
5	Hirai K, Yokoyama M, Asano G and Tanaka S: Expression of cathepsin B and cystatin-C in human colorectal cancer. Human Pathol. 30:680–686. 1999. View Article : Google Scholar
6	Saleh Y, Sebzda T, Warwas M, Kopec W, Ziólkowska J and Siewinski M: Expression of cystatin c in human colorectal cancer tissues. J Exp Ther Oncol. 5:49–53. 2005.PubMed/NCBI
7	Zeng Q, Zhao Y, Yang Y, Zheng G, Wang G, Zhang P, Cui Y, Su S and Li K: Expression of cystatin C in human esophageal cancer. Tumori. 97:203–210. 2011. View Article : Google Scholar : PubMed/NCBI
8	Jiborn T, Abrahamson M, Gadaleanu V, Lundwall A and Bjartell A: Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation. BJU Int. 98:186–196. 2006. View Article : Google Scholar
9	Yano M, Hirai K, Naito Z, Yokoyama M, Ishiwata T, Shiraki Y, Inokuchi M and Asano G: Expression of cathepsin B and cystatin C in human breast cancer. Surg Today. 31:385–389. 2001. View Article : Google Scholar : PubMed/NCBI
10	Sloane BF: Cathepsin B and cystatins: Evidence for a role in cancer progression. Cancer Biol. 1:137–152. 1990.
11	Utsunomiya T, Hara Y, Kataoka A, Morita M, Arakawa H, Mori M and Nishiyama S: Cystatin-like metastasis-associated protein mRNA expression in human colorectal cancer is associated with both liver metastasis and patient survival. Clin Cancer Res. 8:2591–2594. 2002.PubMed/NCBI
12	Kuopio T, Kankaanranta A, Jalava P, Kronqvist P, Kotkansalo T, Weber E and Collan Y: Cysteine proteinase inhibitor cystatin A in breast cancer. Cancer Res. 58:432–436. 1998.PubMed/NCBI
13	Leto G, Tuminello FM, Pizzolanti G, Montallo G, Soresi M and Gebbia N: Lysosomal cathepsins B and L and stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: Potential clinical implications. Oncology. 54:79–83. 1997. View Article : Google Scholar : PubMed/NCBI
14	Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N and Vrhovec I: Cathepsin B, H, L and their inhibitors stefin A and cystatin-C in sera of melanoma patients. Clin Cancer Res. 3:1815–1822. 1997.PubMed/NCBI
15	Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ and Brunner N: Custeine proteinase inhibitors stefin-A, stefin-B, and cystatin-C in sera from patients with colorectal cancer: Relation to prognosis. Clin Cancer Res. 6:505–511. 2000.PubMed/NCBI
16	Ohara G, Miyazaki K, Kurishima K, Kagohashi K, Ishikawa H, Satoh H and Hizawa N: Serum levels of cystatin-C in elderly lung cancer patients. Oncol Lett. 3:303–306. 2012. View Article : Google Scholar : PubMed/NCBI
17	Decock J, Obermajer N, Vozelj S, Hendricks W, Paridaens R and Kos J: Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. Int J Biol Markers. 23:161–168. 2008. View Article : Google Scholar : PubMed/NCBI
18	Rha SY, Yang WI, Gong SJ, Kim JJ, Yoo NC, Roh JK, Min JS, Lee KS, Kim BS and Chung HC: Correlation of tissue and blood plasminogen activation system in breast cancer. Cancer Lett. 150:137–145. 2000. View Article : Google Scholar : PubMed/NCBI
19	Hwang SJ, Yang Q, Meigs JB, Pearce EN and Fox CS: A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study. BMC Med Genet. 8 Suppl 1:S102007. View Article : Google Scholar : PubMed/NCBI
20	Finney H, Bates CJ and Price CP: Plasma cystatin C determinations in healthy elderly population. Arch Gerontol Geriatr. 29:75–94. 1999. View Article : Google Scholar : PubMed/NCBI
21	Norlund L, Grubb A, Fex G, Leksell H, Nilsson JE, Schenck H and Hultberg B: The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal f unction as determined by plasma cystatin C. Clin Chem Lab Med. 36:175–178. 1998. View Article : Google Scholar : PubMed/NCBI
22	Stabuc B, Vrhovec L, Stabuc-Silih M and Cizej TE: Improved prediction of decreased creatinine clearance by serum cystatin C: Use in cancer patients before and during chemotherapy. Clin Chemis. 46:193–197. 2000.
23	Kume M, Yasui H, Yoshikawa Y, Horinouchi M, Higashiguchi K, Kobayashi Y, Kuroda D, Hirano T, Hirai M and Nakamura T: Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients. Cancer Chemother Pharmacol. 69:1537–1544. 2012. View Article : Google Scholar : PubMed/NCBI
24	Laurent-Matha V, Huesgen PF, Masson O, Derocq D, Prébois C, Gary-Bobo M, Lecaille F, Rebiére B, Meurice G, Oréar C, et al: Proteolysis of cystatin-C by cathepsin D in the breast cancer microenvironment. FASEB J. 26:5172–5181. 2012. View Article : Google Scholar : PubMed/NCBI
25	Nishikawa H, Ozaki Y, Nakanishi T, Blomgren K, Tada T, Arakawa A and Suzumori K: The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol. 92:881–886. 2004. View Article : Google Scholar : PubMed/NCBI
26	Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL and Bjartell A: Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells vis MAPK/Erk and androgen receptor pathways. PLos One. 4:e79532009. View Article : Google Scholar : PubMed/NCBI
27	Sokol JP and Schiemann WP: Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res. 2:183–195. 2004.PubMed/NCBI
28	Tian M and Schiemann WP: Preclinical efficacy of cystatin C to target the oncogenic activity of transforming growth factor Beta in breast cancer. Transl Oncol. 2:174–183. 2009. View Article : Google Scholar : PubMed/NCBI
29	Vigneswaran N, Wu J, Muller S, Zacharias W, Narendran S and Middleton L: Expression analysis of cystatin C and M in laser-capture microdissectioned human breast cancer cells-a preliminary study. Pathol Res Pract. 200:753–762. 2005. View Article : Google Scholar : PubMed/NCBI